- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 277/22 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 277/22
Total number of patents in this class: 191
10-year publication summary
|
16
|
7
|
15
|
18
|
13
|
8
|
17
|
7
|
7
|
5
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The University of Toledo | 428 |
12 |
| Bristol-myers Squibb Company | 4872 |
8 |
| Kyoto University | 2799 |
6 |
| Sumitomo Chemical Company, Limited | 9027 |
5 |
| BASF SE | 20874 |
4 |
| Allergan, Inc. | 2361 |
4 |
| Cadila Healthcare Limited | 318 |
4 |
| Solutia Canada Inc | 44 |
4 |
| Sanofi | 4034 |
4 |
| Glaxo Group Limited | 4128 |
3 |
| The Board of Trustees of the University of Illinois | 2685 |
3 |
| Duke University | 3063 |
3 |
| Southern Research Institute | 210 |
3 |
| XENIOPRO GmbH | 15 |
3 |
| F. Hoffmann-La Roche AG | 7932 |
2 |
| Hoffmann-La Roche Inc. | 3400 |
2 |
| Syngenta Participations AG | 1908 |
2 |
| Abbott Laboratories | 2411 |
2 |
| Auspex Pharmaceuticals, Inc. | 187 |
2 |
| Beijing Molecule Science and Technology Co., Ltd. | 12 |
2 |
| Other owners | 113 |